The Application Value of Artificial Intelligence in MRI Precision Diagnosis and Treatment of Bladder Cancer
Prospective Multi-center Clinical Study on the Application Value of Artificial Intelligence in MRI Precision Diagnosis and Treatment of Bladder Cancer
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210000
- Recruiting
- The First Affiliated Hospital of Nanjing Medical University
-
Contact:
- Qiang Lu
- Phone Number: 13505196501
- Email: dxhlvqiang@163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Preoperative examination prompts the patient to be bladder cancer;
- There is no limit on the gender;
- The age of 18 years old or more;
- Can provide preoperative MRI images;
- Agree to provide personal basic clinical information and pathological and imaging data for scientific research, and sign informed consent;
- Agree to provide monitoring results during follow-up monitoring for recurrence.
Exclusion Criteria:
- Patient was unable to provide preoperative MRI images, including MRI images after neoadjuvant therapy and before surgery;
- Patients with incomplete pathological information of samples were unable to provide accurate staging and grading information;
- Patients cannot be operated on due to their own reasons: severe heart failure, acute myocardial infarction, severe heart and lung diseases, etc., they cannot tolerate normal surgical treatment;
- Patients who had recently undergone surgery (e.g., TURBT) prior to MRI examination;
- The researcher thinks there are any conditions that may impair the subject or cause the subject to fail to meet or perform study requirements;
- Patients unable to provide written informed consent.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To explore the application value of artificial intelligence in the precise diagnosis and treatment of bladder tumor, and to improve the accuracy of MRI diagnosis of bladder cancer stage and grade through artificial intelligence.
Time Frame: 1 year
|
2、Through Concordance analysis of artificial intelligence diagnosis assay results with gold standard results of surgery, the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) of artificial intelligence diagnosis before the operation.
|
1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall survival
Time Frame: 3 years after surgery
|
The correlation between artificial intelligence model and OS in bladder cancer patients was analyzed to preliminarily verify the potential ability of artificial intelligence model results in predicting the prognosis of bladder cancer patients.
|
3 years after surgery
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
recurrence-free survival
Time Frame: 3 years after surgery
|
The correlation between artificial intelligence model and RFS in bladder cancer patients was analyzed to preliminarily verify the potential ability of artificial intelligence model results in predicting the prognosis of bladder cancer patients.
|
3 years after surgery
|
|
progression-free survival
Time Frame: 3 years after surgery
|
The correlation between artificial intelligence model and PFS in bladder cancer patients was analyzed to preliminarily verify the potential ability of artificial intelligence model results in predicting the prognosis of bladder cancer patients.
|
3 years after surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
General Publications
- Panebianco V, Narumi Y, Altun E, Bochner BH, Efstathiou JA, Hafeez S, Huddart R, Kennish S, Lerner S, Montironi R, Muglia VF, Salomon G, Thomas S, Vargas HA, Witjes JA, Takeuchi M, Barentsz J, Catto JWF. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol. 2018 Sep;74(3):294-306. doi: 10.1016/j.eururo.2018.04.029. Epub 2018 May 10.
- Wang H, Luo C, Zhang F, Guan J, Li S, Yao H, Chen J, Luo J, Chen L, Guo Y. Multiparametric MRI for Bladder Cancer: Validation of VI-RADS for the Detection of Detrusor Muscle Invasion. Radiology. 2019 Jun;291(3):668-674. doi: 10.1148/radiol.2019182506. Epub 2019 Apr 23.
- Suarez-Ibarrola R, Hein S, Reis G, Gratzke C, Miernik A. Current and future applications of machine and deep learning in urology: a review of the literature on urolithiasis, renal cell carcinoma, and bladder and prostate cancer. World J Urol. 2020 Oct;38(10):2329-2347. doi: 10.1007/s00345-019-03000-5. Epub 2019 Nov 5.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2021-SR-409
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.